Importantly, in clinical settings, dysregulation of this Kindlin-2:Integrins:TβRI axis has implications in diseases such as cancer, where aberrant integrin activation and TGF-β signaling are hallmarks of cancer progression, and Kindlin-2 emerges as a potential key player bridging these pathways. Here, FERMT2 is linked to cancer.